Nektar Therapeutics NKTR Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's stock issuance proceeds?
- Nektar Therapeutics (NKTR) reported stock issuance proceeds of $1.07B in Q2 2026.
- How has Nektar Therapeutics's stock issuance proceeds changed year-over-year?
- Nektar Therapeutics's stock issuance proceeds increased by 506582.5% year-over-year, from $211K to $1.07B.
- What is the long-term trend for Nektar Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Nektar Therapeutics's stock issuance proceeds has grown at a -59.8% compound annual growth rate (CAGR), from $33.24M to $866K.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.